Role of Serotonin in Angiogenesis in Diabetes

  • Masaaki Iwabayashi
  • Yoshiaki Taniyama
  • Junya Azuma
  • Fumihiro Sanada
  • Kazuma Iekushi
  • Hiromi Rakugi
  • Ryuichi MorishitaEmail author
Part of the Advances in Biochemistry in Health and Disease book series (ABHD, volume 6)


Serotonin (5-hydroxytryptamine, 5-HT) is a monoaminergic neurotransmitter synthesized from tryptophan, which is one of the essential amino acids, by mostly enterochromaffin cells in the gut. 5-HT receptors (15 subtypes) are distributed in tissues throughout the body and have diverse effects and play a crucial role in central and peripheral functions. The cardiovascular system is no exception; most of the 5-HT receptor subtypes have been shown to exist and be involved in cardiovascular regulation in both physiological and pathological conditions. Particularly in the vasculature, 5-HT is known to regulate vascular tonus and vascular cell proliferation by the balance of smooth muscle and endothelial 5-HT receptors. Under pathological conditions like diabetes mellitus (DM) and peripheral artery disease (PAD), serum 5-HT level is known to increase and is the hallmark of both pathological conditions. In these conditions, contractile activity of smooth muscle 5-HT2A receptor is increased; thus, 5-HT-mediated vasodilation and endothelial proliferation are inhibited, leading to diminished angiogenesis and peripheral circulation. However, blockade of 5-HT2A by clinically available drugs in a diabetic state enhances angiogenesis and vasodilation. As selective 5-HT2A blocker is widely used to treat PAD patients in clinical practice, the enhancement of angiogenesis, in addition to inhibition of vasoconstriction, might provide a unique treatment combination for therapeutic angiogenesis under a diabetic condition.


Serotonin 5-Hydroxytryptamine Angiogenesis Diabetes mellitus Peripheral artery disease 


  1. 1.
    Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152PubMedGoogle Scholar
  2. 2.
    Merritt JH, Chamness AF, Allen SJ (1978) Studies on blood-brain barrier permeability after microwave-radiation. Radiat Environ Biophys 15:367–377PubMedGoogle Scholar
  3. 3.
    Barter R, Pearse AG (1955) Mammalian enterochromaffin cells as the source of serotonin (5-hydroxytryptamine). J Pathol Bacteriol 69:25–31PubMedGoogle Scholar
  4. 4.
    Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin. Annu Rev Med 60:355–366PubMedGoogle Scholar
  5. 5.
    Leathwood PD (1987) Tryptophan availability and serotonin synthesis. Proc Nutr Soc 46:143–156PubMedGoogle Scholar
  6. 6.
    Markus CR, Olivier B, de Haan EH (2002) Whey protein rich in alpha-lactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stress-vulnerable subjects. Am J Clin Nutr 75:1051–1056PubMedGoogle Scholar
  7. 7.
    Booij L, Merens W, Markus CR, Van der Does AJ (2006) Diet rich in alpha-lactalbumin improves memory in unmedicated recovered depressed patients and matched controls. J Psychopharmacol 20:526–535PubMedGoogle Scholar
  8. 8.
    Walther DJ, Peter JU, Bashammakh S et al (2003) Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299:76PubMedGoogle Scholar
  9. 9.
    Walther DJ, Bader M (2003) A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 66:1673–1680PubMedGoogle Scholar
  10. 10.
    Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533–554PubMedGoogle Scholar
  11. 11.
    Hoyer D, Clarke DE, Fozard JR (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157–203PubMedGoogle Scholar
  12. 12.
    Weiss O (1896) Ueber die Wirkungen von Blutserum-Injectionen ins Blut. Archiv Ges Physiol Menschen Thie LXV:215–230Google Scholar
  13. 13.
    Ramage AG, Villalon CM (2008) 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 29(9):472–481PubMedGoogle Scholar
  14. 14.
    Doggrell SA (2003) The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin Investig Drugs 12:805–823PubMedGoogle Scholar
  15. 15.
    Mylecharane EJ (1990) Mechanisms involved in serotonin-induced vasodilatation. Blood Vessels 27:116–126PubMedGoogle Scholar
  16. 16.
    Haugen G, Mellembakken J, Stray-Pedersen S (1997) Characterization of the vasodilatatory response to serotonin in human umbilical arteries perfused in vitro. The influence of the endothelium. Early Hum Dev 47:185–193PubMedGoogle Scholar
  17. 17.
    Watts SW, Morrison SF, Davis RP, Barman SM (2012) Serotonin and blood pressure regulation. Pharmacol Rev 64:359–388PubMedGoogle Scholar
  18. 18.
    Nilsson T, Longmore J, Shaw D et al (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 372:49–56PubMedGoogle Scholar
  19. 19.
    Gilmore B, Michael M (2011) Treatment of acute migraine headache. Am Fam Physician 83:271–280PubMedGoogle Scholar
  20. 20.
    Vanhoutte PM (1998) Endothelial dysfunction and vascular disease. Verh K Acad Geneeskd Belg 60:251–266Google Scholar
  21. 21.
    Auch-Schwelk W, Paetsch I, Krackhardt F et al (2000) Modulation of contractions to ergonovine and methylergonovine by nitric oxide and thromboxane A2 in the human coronary artery. J Cardiovasc Pharmacol 36:631–639PubMedGoogle Scholar
  22. 22.
    Ellis ES, Byrne C, Murphy OE et al (1995) Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol 114:400–404PubMedGoogle Scholar
  23. 23.
    Centurion D, Sanchez-Lopez A, Ortiz MI et al (2000) Mediation of 5-HT-induced internal carotid vasodilatation in GR127935- and ritanserin-pretreated dogs by 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol 362:169–176PubMedGoogle Scholar
  24. 24.
    Golino P, Piscione F, Willerson JT et al (1991) Divergent effects of serotonin on coronary-­artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 324:641–648PubMedGoogle Scholar
  25. 25.
    Ishida T, Kawashima S, Hirata K et al (2001) Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation 103:1289–1295PubMedGoogle Scholar
  26. 26.
    Criqui MH, Langer RD, Fronek A et al (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326:381–386PubMedGoogle Scholar
  27. 27.
    Criqui MH (2001) Peripheral arterial disease–epidemiological aspects. Vasc Med 6:3–7PubMedGoogle Scholar
  28. 28.
    Hirsch AT, Hartman L, Town RJ, Virnig BA (2008) National health care costs of peripheral arterial disease in the Medicare population. Vasc Med 13:209–215PubMedGoogle Scholar
  29. 29.
    Hirsch AT, Halverson SL, Treat-Jacobson D et al (2001) The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vasc Med 6:87–96PubMedGoogle Scholar
  30. 30.
    McDermott MM (2006) The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance. Cleve Clin J Med 73:S2–S7PubMedGoogle Scholar
  31. 31.
    Pell JP (1995) Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group. Eur J Vasc Endovasc Surg 9:469–472PubMedGoogle Scholar
  32. 32.
    Izquierdo-Porrera AM, Gardner AW, Bradham DD et al (2005) Relationship between objective measures of peripheral arterial disease severity to self-reported quality of life in older adults with intermittent claudication. J Vasc Surg 41:625–630PubMedGoogle Scholar
  33. 33.
    Tsai JC, Chan P, Wang CH et al (2002) The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med 252:448–455PubMedGoogle Scholar
  34. 34.
    Gornik HL, Creager MA (2006) Contemporary management of peripheral arterial disease: I. Cardiovascular risk-factor modification. Cleve Clin J Med 73:S30–S37PubMedGoogle Scholar
  35. 35.
    Zheng ZJ, Sharrett AR, Chambless LE et al (1997) Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 131:115–125PubMedGoogle Scholar
  36. 36.
    Newman AB, Shemanski L, Manolio TA et al (1999) Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19:538–545PubMedGoogle Scholar
  37. 37.
    Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH (1993) Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 270:487–489PubMedGoogle Scholar
  38. 38.
    Leng GC, Fowkes FG, Lee AJ et al (1996) Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J 313:1440–1444Google Scholar
  39. 39.
    Hirsch AT, Criqui MH, Treat-Jacobson D et al (2001) Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286:1317–1324PubMedGoogle Scholar
  40. 40.
    Cimminiello C (2002) PAD. Epidemiology and pathophysiology. Thromb Res 106:V295–V301PubMedGoogle Scholar
  41. 41.
    Anon (1991) Second European consensus document on chronic critical leg ischemia. Circulation 84:IV1–IV26Google Scholar
  42. 42.
    Tapp RJ, Zimmet PZ, Harper CA et al (2004) Diabetes care in an Australian population: frequency of screening examinations for eye and foot complications of diabetes. Diabetes Care 27:688–693PubMedGoogle Scholar
  43. 43.
    Gregg EW, Sorlie P, Paulose-Ram R et al (2004) Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 National Health and Nutrition Examination Survey. Diabetes Care 27:1591–1597PubMedGoogle Scholar
  44. 44.
    Dolan NC, Liu K, Criqui MH et al (2002) Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 25:113–120PubMedGoogle Scholar
  45. 45.
    Prompers L, Schaper N, Apelqvist J et al (2008) Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 51:747–755PubMedGoogle Scholar
  46. 46.
    Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570–2581PubMedGoogle Scholar
  47. 47.
    Lanzer P (2001) Topographic distribution of peripheral arteriopathy in non-diabetics and type 2 diabetics. Z Kardiol 90:99–103PubMedGoogle Scholar
  48. 48.
    Faglia E, Clerici G, Clerissi J et al (2009) Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. Diabetes Care 32:822–827PubMedGoogle Scholar
  49. 49.
    Kamalesh M, Shen J (2009) Diabetes and peripheral arterial disease in men: trends in prevalence, mortality, and effect of concomitant coronary disease. Clin Cardiol 32:442–446PubMedGoogle Scholar
  50. 50.
    Larsson J, Agardh CD, Apelqvist J, Stenstrom A (1998) Long-term prognosis after healed amputation in patients with diabetes. Clin Orthop Relat Res (350):149–158Google Scholar
  51. 51.
    Malmstedt J, Leander K, Wahlberg E et al (2008) Outcome after leg bypass surgery for critical limb ischemia is poor in patients with diabetes: a population-based cohort study. Diabetes Care 31:887–892PubMedGoogle Scholar
  52. 52.
    Currie CJ, Morgan CL, Peters JR (1998) The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 21:42–48PubMedGoogle Scholar
  53. 53.
    De Vivo S, Palmer-Kazen U, Kalin B, Wahlberg E (2005) Risk factors for poor collateral development in claudication. Vasc Endovascular Surg 39:519–524PubMedGoogle Scholar
  54. 54.
    Waltenberger J (2001) Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 49:554–560PubMedGoogle Scholar
  55. 55.
    Abaci A, Oguzhan A, Kahraman S et al (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99:2239–2242PubMedGoogle Scholar
  56. 56.
    Yan J, Tie G, Park B, Yan Y et al (2009) Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: roles of endothelial nitric oxide synthase and endothelial progenitor cells. J Vasc Surg 50:1412–1422PubMedGoogle Scholar
  57. 57.
    Rivard A, Silver M, Chen D et al (1999) Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 154:355–363PubMedGoogle Scholar
  58. 58.
    Taniyama Y, Morishita R, Hiraoka K et al (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 104:2344–2350PubMedGoogle Scholar
  59. 59.
    Schiekofer S, Galasso G, Sato K et al (2005) Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 25:1603–1609PubMedGoogle Scholar
  60. 60.
    van Golde JM, Ruiter MS, Schaper NC et al (2008) Impaired collateral recruitment and outward remodeling in experimental diabetes. Diabetes 57:2818–2823PubMedGoogle Scholar
  61. 61.
    Ruiter MS, van Golde JM, Schaper NC et al (2010) Diabetes impairs arteriogenesis in the peripheral circulation: review of molecular mechanisms. Clin Sci 119:225–238PubMedGoogle Scholar
  62. 62.
    Malyszko J, Urano T, Knofler R et al (1994) Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 75:569–576PubMedGoogle Scholar
  63. 63.
    Barradas MA, Gill DS, Fonseca VA et al (1988) Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 18:399–404PubMedGoogle Scholar
  64. 64.
    Dallinger KJ, Jennings PE, Toop MJ et al (1987) Platelet aggregation and coagulation factors in insulin dependent diabetics with and without microangiopathy. Diabet Med 4:44–48PubMedGoogle Scholar
  65. 65.
    Pietraszek MH, Takada Y, Takada A et al (1992) Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 66:765–774PubMedGoogle Scholar
  66. 66.
    Robless PA, Okonko D, Lintott P et al (2003) Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 25:16–22PubMedGoogle Scholar
  67. 67.
    Hara K, Hirowatari Y, Yoshika M et al (2004) The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease. J Lab Clin Med 144:31–37PubMedGoogle Scholar
  68. 68.
    Maurer-Spurej E (2005) Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell Mol Life Sci 62:159–170PubMedGoogle Scholar
  69. 69.
    Tanaka N (2009) Pharmacological studies on responsiveness of 5-hydroxytryptamine in overcoming perioperative spasm of coronary artery bypass graft. Yakugaku Zasshi 129:1049–1053PubMedGoogle Scholar
  70. 70.
    Boston PC, Hodgson WC (1997) Changes in reactivity towards 5-hydroxytryptamine in the renal vasculature of the diabetic spontaneously hypertensive rat. J Hypertens 15:769–774PubMedGoogle Scholar
  71. 71.
    Brezun JM, Daszuta A (2000) Serotonin may stimulate granule cell proliferation in the adult hippocampus, as observed in rats grafted with foetal raphe neurons. Eur J Neurosci 12:391–396PubMedGoogle Scholar
  72. 72.
    Nebigil CG, Choi DS, Dierich A et al (2000) Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A 97:9508–9513PubMedGoogle Scholar
  73. 73.
    Seuwen K, Magnaldo I, Pouyssegur J (1988) Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 335:254–256PubMedGoogle Scholar
  74. 74.
    Takuwa N, Ganz M, Takuwa Y et al (1989) Studies of the mitogenic effect of serotonin in rat renal mesangial cells. Am J Physiol 257:F431–F439PubMedGoogle Scholar
  75. 75.
    Tutton PJ, Barkla DH (1986) Serotonin receptors influencing cell proliferation in the jejunal crypt epithelium and in colonic adenocarcinomas. Anticancer Res 6:1123–1126PubMedGoogle Scholar
  76. 76.
    Hanley MR (1989) Mitogenic neurotransmitters. Nature 340:97PubMedGoogle Scholar
  77. 77.
    Ishizuka J, Beauchamp RD, Townsend CM et al (1992) Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol 150:1–7PubMedGoogle Scholar
  78. 78.
    Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA (1986) Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A 83:674–678PubMedGoogle Scholar
  79. 79.
    Kavanaugh WM, Williams LT, Ives HE, Coughlin SR (1988) Serotonin-induced deoxyribonucleic acid synthesis in vascular smooth muscle cells involves a novel, pertussis toxin-­sensitive pathway. Mol Endocrinol 2:599–605PubMedGoogle Scholar
  80. 80.
    Araki S, Kawahara Y, Fukuzaki H, Takai Y (1990) Serotonin plays a major role in serum-­induced phospholipase C-mediated hydrolysis of phosphoinositides and DNA synthesis in vascular smooth muscle cells. Atherosclerosis 83:29–34PubMedGoogle Scholar
  81. 81.
    Lee SL, Wang WW, Moore BJ, Fanburg BL (1991) Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ Res 68:1362–1368PubMedGoogle Scholar
  82. 82.
    Pakala R, Willerson JT, Benedict CR (1994) Mitogenic effect of serotonin on vascular endothelial cells. Circulation 90:1919–1926PubMedGoogle Scholar
  83. 83.
    Pakala R, Sheng WL, Benedict CR (1999) Serotonin fails to induce proliferation of endothelial cells preloaded with eicosapentaenoic acid and docosahexaenoic acid. Atherosclerosis 145:137–146PubMedGoogle Scholar
  84. 84.
    Pakala R, Benedict CR (1998) Effect of serotonin and thromboxane A2 on endothelial cell proliferation: effect of specific receptor antagonists. J Lab Clin Med 131:527–537PubMedGoogle Scholar
  85. 85.
    Asada M, Ebihara S, Yamanda S et al (2009) Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation. Neoplasia 11:408–417PubMedGoogle Scholar
  86. 86.
    Tutton PJ, Steel GG (1979) Influence of biogenic amines on the growth of xenografted human colorectal carcinomas. Br J Cancer 40:743–749PubMedGoogle Scholar
  87. 87.
    McDuffie JE, Motley ED, Limbird LE, Maleque MA (2000) 5-Hydroxytryptamine stimulates phosphorylation of p44/p42 mitogen-activated protein kinase activation in bovine aortic endothelial cell cultures. J Cardiovasc Pharmacol 35:398–402PubMedGoogle Scholar
  88. 88.
    Nishikawa T, Tsuno NH, Shuno Y et al (2010) Antiangiogenic effect of a selective 5-HT4 receptor agonist. J Surg Res 159:696–704PubMedGoogle Scholar
  89. 89.
    Humphrey PP, Feniuk W, Perren MJ et al (1988) GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94:1123–1132PubMedGoogle Scholar
  90. 90.
    Launay JM, Herve P, Peoc’h K et al (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129–1135PubMedGoogle Scholar
  91. 91.
    Fujita M, Minamino T, Sanada S et al (2004) Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. J Mol Cell Cardiol 37:1219–1223PubMedGoogle Scholar
  92. 92.
    Takano S, Hoshino Y, Li L et al (2004) Dual roles of 5-hydroxytryptamine in ischemia-­reperfusion injury in isolated rat hearts. J Cardiovasc Pharmacol Ther 9:43–50PubMedGoogle Scholar
  93. 93.
    MacLean MR, Deuchar GA, Hicks MN et al (2004) Overexpression of the 5-­hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 109:2150–2155PubMedGoogle Scholar
  94. 94.
    Esteve JM, Launay JM, Kellermann O, Maroteaux L (2007) Functions of serotonin in hypoxic pulmonary vascular remodeling. Cell Biochem Biophys 47:33–44PubMedGoogle Scholar
  95. 95.
    Kahn AM, Allen JC, Seidel CL, Song T (1994) Insulin inhibits serotonin-induced Ca2+ influx in vascular smooth muscle. Circulation 90:384–390PubMedGoogle Scholar
  96. 96.
    Ohkura M, Tanaka N, Kobayashi H et al (2005) Insulin induces internalization of the 5-HT2A receptor expressed in HEK293 cells. Eur J Pharmacol 518:18–21PubMedGoogle Scholar
  97. 97.
    Bir SC, Fujita M, Marui A et al (2008) New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia. Circulation 72:633–640Google Scholar
  98. 98.
    Li TS, Furutani A, Takahashi M et al (2006) Impaired potency of bone marrow mononuclear cells for inducing therapeutic angiogenesis in obese diabetic rats. Am J Physiol Heart Circ Physiol 290:H1362–H1369PubMedGoogle Scholar
  99. 99.
    Iwabayashi M, Taniyama Y, Sanada F et al (2012) Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5-HT1B/Akt/eNOS pathway in diabetic mice. Atherosclerosis 220:337–342PubMedGoogle Scholar
  100. 100.
    Murohara T, Asahara T, Silver M et al (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101:2567–2578PubMedGoogle Scholar
  101. 101.
    Zehender M, Meinertz T, Hohnloser S et al (1989) Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Am J Cardiol 63:826–832PubMedGoogle Scholar
  102. 102.
    Ito K, Notsu T (1991) Effect of sarpogrelate hydrochloride (MCI-9042) on peripheral circulation of chronic arterial occlusive disease. J Clin Ther Med 7:1243–1251Google Scholar
  103. 103.
    Norgren L, Jawien A, Matyas L et al (2006) Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A Phase II European Study. Vasc Med 11:75–83PubMedGoogle Scholar
  104. 104.
    Miyazaki M, Higashi Y, Goto C et al (2007) Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol 49:221–227PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Masaaki Iwabayashi
    • 1
  • Yoshiaki Taniyama
    • 1
    • 2
  • Junya Azuma
    • 1
    • 2
  • Fumihiro Sanada
    • 1
  • Kazuma Iekushi
    • 1
    • 2
  • Hiromi Rakugi
    • 2
  • Ryuichi Morishita
    • 1
    Email author
  1. 1.Department of Clinical Gene TherapyOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Department of Geriatric Medicine and NephrologyOsaka University Graduate School of MedicineSuitaJapan

Personalised recommendations